Abstract Malaria resurgence in 2022 saw 249 million clinical cases and 608,000 deaths, mostly in children under five. The WHO-approved circumsporozoite protein (CSP)-targeting vaccines, RTS,S and R21, remain limited in availability. Strong humoral responses are crucial for sporozoite neutralization before hepatocyte infection, yet first-generation vaccines provide suboptimal protection, necessitating improved strategies.
Richard Markham
As seen in:
Nature,
Frontiers,
The Conversation,
Australian Geographic,
Islands Business,
I Want The News
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Richard
Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack